Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04386057 · ClinicalTrials.gov registry record · Phase 2
LY3214996 +/- HCQ in Pancreatic Cancer
A Phase 2 study of Pancreatic Cancer and Advanced Cancer, sponsored by Kimberly Perez, MD.
- Completed
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
- 4
- Study locations
NCT04386057 is a Phase 2 study of Pancreatic Cancer and Advanced Cancer that has completed, run by Kimberly Perez, MD. The registered enrollment target is 52 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (87% lower). The trial reports 4 study locations across 2 states.
The verdict
NCT04386057, a Phase 2 study of Pancreatic Cancer and Advanced Cancer, has completed, sponsored by Kimberly Perez, MD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study is evaluating the safety and efficacy of combining the study drug LY3214996 with hydroxychloroquine sulfate (HCQ) in patients with advanced pancreatic cancer.
Conditions Studied
Interventions
- DRUG Hydroxychloroquine Sulfate
- DRUG LY3214996
Study Locations (4)
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
- Dana-Farber Cancer Institute - Boston
- Beth Israel Deaconess Medical Center - Boston
North Carolina
- The University of North Carolina at Chapel Hill - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2020-05-27 |
| Est. Completion | 2024-02-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04386057
The ClinicalTrials.gov registry entry for NCT04386057 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (87% lower). The listed sponsor is Kimberly Perez, MD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 2 interventions - of which Hydroxychloroquine Sulfate is the first listed.
NCT04386057 reports 4 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, North Carolina.
Frequently Asked Questions
What is clinical trial NCT04386057 about?
NCT04386057 is a clinical study titled "LY3214996 +/- HCQ in Pancreatic Cancer". This study is evaluating the safety and efficacy of combining the study drug LY3214996 with hydroxychloroquine sulfate (HCQ) in patients with advanced pancreatic cancer.
What is the current status of trial NCT04386057?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2020-05-27. Estimated completion is 2024-02-05.
What conditions does trial NCT04386057 study?
This clinical trial studies the following conditions: Pancreatic Cancer, Advanced Cancer.
What interventions are being tested in trial NCT04386057?
The interventions under investigation include: Hydroxychloroquine Sulfate (DRUG), LY3214996 (DRUG).
Who is sponsoring clinical trial NCT04386057?
This trial is sponsored by Kimberly Perez, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04386057 being conducted?
This trial has 4 study locations across Massachusetts, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial
RECRUITING · Phase 2
-
Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer
RECRUITING · Phase 2
-
Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples
RECRUITING · Phase 2
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.